TNF and Crohn disease: For example, the highly variable clinical response to immunomodulatory therapies, such as methotrexate[40] or anti-TNF monoclonal antibodies[41], may be influenced by the burden of disease-associated variants in Crohn’s disease Group 1 (Fig 7).